A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)

NCT07742215 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloma Multiple

Interventions

DRUG: BCD-248 + daratumumab
DRUG: Daratumumab + pomalidomide + dexamethasone

Sponsor

Biocad